All In Biotech

NDA 022544 · Almatica

Gralise

Gabapentin · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Jan 28, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

501

111 Phase 3, 25 recruiting

FAERS reports

300,733

189,916 serious, 29,651 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2026.

GRALISE is indicated for the management of postherpetic neuralgia. GRALISE is not substitutable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration. GRALISE is indicated for the management of Postherpetic Neuralgia (PHN). Important Limitation: GRALISE is not substitutable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration (See Warnings and Precautions )

Mechanism: The mechanism of action by which gabapentin exerts its analgesic action is unknown but in animal models of analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli). Gabapentin prevents pain-related responses in several models of neuropathic pain in rats and mice (e.g., spinal nerve ligation models, spinal cord injury model, acute herpes zoster infection model). Gabapentin also decreases pain-related responses after peripheral inflammation (carrageenan footpad test, late phase of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • GRALISE · GABAPENTIN 750MG · TABLET, ORAL · Prescription · TE AB
  • GRALISE · GABAPENTIN 600MG · TABLET, ORAL · Prescription · TE AB2
  • GRALISE · GABAPENTIN 900MG · TABLET, ORAL · Prescription · TE AB
  • GRALISE · GABAPENTIN 450MG · TABLET, ORAL · Prescription · TE AB
  • GRALISE · GABAPENTIN 300MG · TABLET, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Gabapentin" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective23,993
  • fatigue21,544
  • nausea18,926
  • off label use17,906
  • pain17,036
  • diarrhoea15,598
  • headache14,835
  • dizziness13,449
  • fall12,687
  • dyspnoea11,776
  • vomiting10,041
  • death9,961

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004874
20051,392
20061,193
20071,391
20081,882
20092,372
20103,430
20113,989
20126,183
20137,179
20149,856
201516,498
201621,037
201722,746
201827,102
201929,628
202025,935
202122,045
202220,707
202320,248
202419,735
202520,633
202614,677

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gralise (Gabapentin)

2024 spending

$12.5M

Beneficiaries

2,970

12,576 claims

Per beneficiary

$4,211

$10.89 per unit

View as table
YearSpending
2020$0
2021$15,966,009
2022$22,803,157
2023$23,008,454
2024$12,506,958

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,415 on PubMed

Sponsor: Almatica

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.